NGL Fine-ChemNSE:NGLFINE -2.72%78 EBITDA Margin % is 16.00% as of Mar. 2026, which is 23% below its 10-year median of 20.88. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,836.47 (Fairly Valued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, NGL Fine-Chem ranks better than 62.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. NGL Fine-Chem's EBITDA for the
three
months ended in Mar. 2026 was ₹239 Mil. NGL Fine-Chem's Revenue for the
three
months ended in Mar. 2026 was ₹1,492 Mil. Therefore, NGL Fine-Chem's EBITDA margin for the quarter that ended in Mar. 2026 was 16.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
NGL Fine-Chem EBITDA Margin % Related Terms
NGL Fine-Chem EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a EBITDA Margin % of 16.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NGL Fine-Chem and its competitors. This is 23% below median its historical median of 20.88. Over the past decade, NGL Fine-Chem's EBITDA Margin % has ranged from 11.54 to 34.42. According to the industry distribution chart, NGL Fine-Chem ranks #357 out of 955 companies in the Drug Manufacturers industry, placing it in the top 37.4%.
Is NGL Fine-Chem's EBITDA Margin % too high?
NGL Fine-Chem's current EBITDA Margin % of 16.00% is 23% below median its 10-year median of 20.88. Over the past 10 years, this metric has ranged from a low of 11.54 to a high of 34.42. The Drug Manufacturers industry median EBITDA Margin % is 12.44. NGL Fine-Chem's value of 16.00% is 28.6% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #357 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #357 out of 955 companies for EBITDA Margin %. This puts NGL Fine-Chem in the upper half of its industry. The industry median EBITDA Margin % is 12.44. NGL Fine-Chem's value of 16.00% is 28.6% above this benchmark. Historically, NGL Fine-Chem's own EBITDA Margin % has ranged from 11.54 to 34.42 over the past decade. While the company's 10-year median is 20.88 vs. the industry median of 12.44, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current EBITDA Margin % of 16.00% is 28.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current EBITDA Margin % is 16.00%, which is 23% below median its own 10-year median of 20.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,836.47, compared to a current price of ₹2,989.90 — trading 5.4% above its estimated fair value. The current EBITDA Margin % is 16.00%, which is 23% below median its 10-year median of 20.88 and 28.6% above the Drug Manufacturers industry median of 12.44. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current EBITDA Margin % is 16.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹2,989.90 is trading 5.4% above its estimated GF Value™ of ₹2,836.47.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
EBITDA Margin %: 16.00% (23% below median its 10-year median of 20.88)
GF Value™: ₹2,836.47 vs. price of ₹2,989.90 (5.4% above fair value)
Industry Position: 28.6% above the Drug Manufacturers median (#357 of 955)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
